EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Event‐free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group

Jonathan Metts iD, Wei Xue, Zhengya Gao, Sapna Oberoi iD, Aaron R Weiss iD, Rajkumar Venkatramani, Douglas J Harrison iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31009 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Jonathan Metts und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sarcoma Department, Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Clinical Trials, Phase II as Topic, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Summer's Way Foundation, Takeda Pharmaceuticals, Cookies for Kid's Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Novel therapies are needed for relapsed and refractory rhabdomyosarcoma (RRMS). Phase II clinical trials in RRMS have typically utilized radiologic response as the primary activity endpoint, an approach that poses several limitations in RRMS. In this analysis, we aimed to estimate an event‐free survival (EFS) endpoint for RRMS that could be used as a benchmark for future studies. Procedure We performed a retrospective study of patients with RRMS enrolling on 13 single‐agent phase II Children's Oncology Group and legacy group trials from 1997 to 2016. All included trials used radiographic response as their primary activity endpoint. Six‐month EFS was estimated from time of trial enrollment with 95% confidence intervals. Clinical characteristics, including trial of enrollment, sex, age, race, histology, number of prior chemotherapies, and radiographic response were evaluated for their impact on 6‐month EFS.

Results

We identified 175 patients across 13 trials. The 6‐month EFS was 16.8% (11.6%–22.8%). No differences were seen in 6‐month EFS based on age, sex, race, or histology. There were nonsignificant trends toward improved 6‐month EFS for patients with less than or equal to two prior lines of therapy versus higher than two, for patients enrolled on trials that achieved their primary radiographic response endpoint versus trials that did not, and for patients who achieved complete or partial response compared to those achieving stable disease.

Conclusions

The prognosis of RRMS enrolled on single‐agent phase II trials is poor. This pooled 6‐month EFS of RRMS on single‐agent trials may be used as a RRMS‐specific benchmark for future single‐agent phase II trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhabdomyosarcomaClinical Trials, Phase II as TopicNeoplasm Recurrence, LocalHumansFemaleMaleChildRetrospective StudiesChild, PreschoolAdolescentInfantSurvival RatePrognosisFollow-Up Studies

Stichwörter der Autor:innen

oncologyphase II clinical trialsrhabdomyosarcoma

Autor:innen und Institutionen

  • Sarcoma Department, Moffitt Cancer Center, Tampa, Florida, USA.
  • Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA.
  • Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
  • Department of Pediatric Hematology/Oncology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
  • Department of Pediatrics, Maine Medical Center, Portland, Maine, USA.
  • Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Jonathan Metts, Sapna Oberoi, Aaron R Weiss, Douglas J Harrison

Förderung

  • Summer's Way Foundation
  • Takeda Pharmaceuticals
  • Cookies for Kid's Cancer
  • NIH HHS
  • St Baldrick's Foundation
  • NCI NIH HHS
  • Friends of TJ Foundation
  • Maddie's Promise Foundation

Zitieren

APA

Metts, J., Xue, W., Gao, Z., Oberoi, S., Weiss, A. R., Venkatramani, R., & Harrison, D. J. (2024). Event‐free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31009

Vancouver

Metts J, Xue W, Gao Z, Oberoi S, Weiss AR, Venkatramani R, et al. Event‐free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31009

BibTeX
@article{Metts2024,
  author = {Metts, Jonathan and Xue, Wei and Gao, Zhengya and Oberoi, Sapna and Weiss, Aaron R and Venkatramani, Rajkumar and Harrison, Douglas J},
  title = {Event‐free survival in relapsed and refractory rhabdomyosarcoma treated on cooperative group phase II trials: A report from the Children's Oncology Group},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31009}
}
Kostenlos starten →